Danaher (NYSE:DHR) Stock Sale Reported by Rep. Kevin Hern

29 Sep 2026, 12:03 by Michael Walen · The Markets Daily

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Danaher Corporation (NYSE:DHR). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Danaher stock on September 2nd. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Danaher Price Performance

Danaher stock opened at $227.51 on Tuesday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $206.57 and a 200 day moving average price of $192.90. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The stock has a market cap of $159.94 billion, a P/E ratio of 40.41, a PEG ratio of 2.80 and a beta of 0.78.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.77 EPS. Sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Main Street Group LTD acquired a new position in shares of Danaher during the first quarter worth $25,000. N.E.W. Advisory Services LLC acquired a new position in Danaher in the second quarter valued at approximately $25,000. Hilton Head Capital Partners LLC purchased a new position in Danaher in the fourth quarter valued at approximately $27,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Danaher by 71.6% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after buying an additional 53 shares during the last quarter. Finally, Evolution Wealth Management Inc. boosted its holdings in shares of Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after buying an additional 104 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DHR. The Goldman Sachs Group raised their target price on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. UBS Group assumed coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. TD Cowen reduced their price objective on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, HSBC decreased their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $230.23.

Get Our Latest Research Report on DHR

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Danaher

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.